Creating benchmarks for ethical pharma, interview with Bioethics International's Jennifer Miller

29 June 2016

Jennifer Miller is the founding president of Bioethics International (BEI), a US-based non-profit organization which aims to improve the ethics and transparency of health care innovation and delivery.

A major focus for BEI is around access to medicines, and as part of this Dr Miller has launched the Good Pharma Scorecard (GPS), an annual ranking of pharmaceutical companies and new drugs on specific ethics and population health performance indicators.

The aim of this index is not so much to highlight wrongdoing, but to recognize good practices in companies, improve trustworthiness and incentivize reform.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK